[AccessWire] GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), A unique company in the MMJ space today that is focused on the medical insurance side of the business is Novus Acquisition & Development (NDEV). Novus provides health insurance and insurance related solutions to the growing wellness and MMJ markets using an innovative cost-saving provider network model that is administered via their wholly-owned Novus Medical Group subsidiary’s Novus MedPlan. The timely rollout of the Novus MedPlan in states where MMJ is legal, which gives patients access to considerable discounts on MMJ products for a modest subscriber fee of under $20 a month, was recently highlighted in Forbes as the number one pick, taking the top slot out of a list of the eight hottest publicly traded companies to draw the interest of investors in this rapidly emerging sector. Read the full article here.
GW Pharmaceuticals PLC- ADR (GWPH) last released quarterly earnings on December 02nd for the period ending September 30th 2014. The company reported actual earnings per share of $0.02 against Zack’s Research estimate of ($0.46). This represents a 104.35% surprise upside to the expected number.
The average broker recommendation according to Zacks is 1.00 based on 3 recommendations. On a consensus basis, analysts have a short term target price of $111.75. Out of 265 companies within the Internet Commerce industry, the company sits at 91. Zacks gives a current quarter EPS estimate of -0.46 and a Strong Buy rating of 1 which is based on short term performance over the next one to three months. Of the companies included in the Zack’s consensus rating, 3 rate the stock a Strong Buy.
About GW Pharmaceuticals
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.